Skip to main content
MACROGENICS INC logo

MACROGENICS INC — Investor Relations & Filings

Ticker · MGNX ISIN · US5560991094 LEI · 5493001KJQUA83L8MH79 US Manufacturing
Open in API
Filings indexed 894 across all filing types
Latest filing 2026-05-20 Declaration of Voting R…
Country US United States of America
Listing US MGNX

About MACROGENICS INC

https://www.macrogenics.com/

MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative antibody-based therapeutics for the treatment of cancer. The company utilizes its proprietary antibody engineering platforms, including the DART (Dual-Affinity Re-Targeting) and TRIDENT technologies, to create novel product candidates. Its pipeline consists of investigational treatments such as monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific antibodies. MacroGenics maintains fully-integrated capabilities, from research and discovery through to GMP (Good Manufacturing Practice) manufacturing, to advance its portfolio of potential medicines for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K “Current Report” under Item 5.07 “Submission of Matters to a Vote of Security Holders,” detailing vote counts and outcomes for proposals at the 2026 Annual Meeting. This is a formal announcement of shareholder voting results, which corresponds to category DVA (Declaration of Voting Results & Voting Rights Announcements).
2026-05-20 English
8-K - MACROGENICS INC (0001125345) (Filer)
Regulatory Filings Classification · 78% confidence The document is a U.S. SEC Form 8-K “Current Report” announcing the company’s quarter-end results and attaching a press release (Exhibit 99.1). It does not contain the full financial report itself, only a regulatory announcement of an event. This aligns with a general regulatory filing rather than an earnings release (ER) or the report itself. Thus, it is classified as a Regulatory Filing (RNS).
2026-05-13 English
8-K - MACROGENICS INC (0001125345) (Filer)
M&A Activity Classification · 89% confidence The document is a Form 8-K “Current Report” describing the entry into a Material Definitive Agreement—specifically an Asset Purchase Agreement—under Item 1.01, whereby the company sells its CDMO operations. This is a corporate transaction involving the sale of assets, fitting within merger & acquisition activity. Therefore it should be classified under Merger & Acquisition (Code: MA).
2026-05-12 English
DEF 14A - MACROGENICS INC (0001125345) (Filer)
Proxy Solicitation & Information Statement
2026-04-08 English
SCHEDULE 13G/A - MACROGENICS INC (0001125345) (Subject)
Major Shareholding Notification
2026-03-27 English
8-K - MACROGENICS INC (0001125345) (Filer)
Board/Management Information Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The key content is the announcement of a director's decision not to stand for re-election and related board changes. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management. The document is short (3198 characters) and contains specific information about a director departure, not a full report or financial data. Therefore, the correct classification is MANG with high confidence.
2026-03-02 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.